Evidence map›Paper›PMID 33762723›Full record

Observational studyBritish journal of cancer2021

Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.

Emad A Rakha, Islam M Miligy, Cecily M Quinn, Elena Provenzano, Abeer M Shaaban, Caterina Marchiò, Michael S Toss, Grace Gallagy, Ciara Murray, Janice Walshe and 10 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Updates on breast biomarkers.Virchows Archiv : an international journal of pathology · 2022
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Emad A RakhaDepartment of Histopathology, Nottingham University Hospitals, Nottingham, UK. emad.rakha@nottingham.ac.uk.ORCID http://orcid.org/0000-0002-5009-5525
Islam M MiligyNottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, Nottingham City Hospital, The University of Nottingham, Nottingham, UK.
Cecily M QuinnHistopathology, Breast Check, Irish National Breast Screening Programme and St. Vincent's University Hospital, Dublin, Ireland.
Elena ProvenzanoDepartment of Pathology, University of Cambridge, Cambridge, UK.
Abeer M ShaabanQueen Elizabeth Hospital Birmingham and Institute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0001-5784-8705
Caterina MarchiòDepartment of Medical Sciences, University of Turin, Turin, Italy.
Michael S TossNottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, Nottingham City Hospital, The University of Nottingham, Nottingham, UK.
Grace GallagyDiscipline of Pathology, School of Medicine, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.
Ciara MurrayHistopathology, Breast Check, Irish National Breast Screening Programme and St. Vincent's University Hospital, Dublin, Ireland.
Janice WalsheHistopathology, Breast Check, Irish National Breast Screening Programme and St. Vincent's University Hospital, Dublin, Ireland.
Ayaka KatayamaNottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, Nottingham City Hospital, The University of Nottingham, Nottingham, UK.
Karim EldibDepartment of Histopathology, Nottingham University Hospitals, Nottingham, UK.
Nahla BadrQueen Elizabeth Hospital Birmingham and Institute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham, UK.
Bruce TanchelQueen Elizabeth Hospital Birmingham and Institute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham, UK.
Rebecca Millican-SlaterDepartment of Histopathology, St James's University Hospital, Leeds, UK.
Colin PurdieDepartment of Breast Pathology, Ninewells Hospital and Medical School, Dundee, UK.
Dave PurnellHistopathology Department, University Hospitals of Leicester, Leicester, UK.
Sarah E PinderDivision of Cancer Studies, King's College London, Guy's Hospital, London, UK.ORCID http://orcid.org/0000-0003-4167-8910
Ian O EllisDepartment of Histopathology, Nottingham University Hospitals, Nottingham, UK.ORCID http://orcid.org/0000-0001-5292-8474
Andrew H S LeeDepartment of Histopathology, Nottingham University Hospitals, Nottingham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group 2 tumours with immunohistochemistry score 2+ and HER2/CEP17 ratio ≥2.0 and HER2 copy number <4.0 signals/cell were re-classified as HER2 negative. This study aims to examine the response of Group 2 tumours to neoadjuvant chemotherapy (NACT).

methods749 BC cases were identified from 11 institutions. The association between HER2 groups and pathological complete response (pCR) was assessed.

results54% of immunohistochemistry HER2 positive (score 3+) BCs showed pCR, compared to 19% of immunohistochemistry 2+ FISH amplified cases. 27% of Group 2 treated with HER2 targeted therapy achieved pCR, compared to 19 and 11% in the combined Groups 1 + 3 and Groups 4 + 5, respectively. No difference in pCR rates was identified between Group 2 and Group 1 or combined Groups 1 + 3. However, Group 2 response rate was higher than Groups 4 + 5 (p = 0.017).

conclusionNo difference in pCR was detected in tumours with a HER2/CEP17 ratio ≥2.0 and a HER2 score 2+ by IHC when stratified by HER2 gene copy number. Our data suggest that ASCO/CAP HER2 Group 2 carcinomas should be evaluated further with respect to eligibility for HER2 targeted therapy.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesGene DosageAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCase-Control StudiesCohort StudiesFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceNeoadjuvant TherapyNeoplasm GradingRetrospective StudiesBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID33762723
PMCPMC8144199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.